Early Identification of Systemic Mastocytosis: Insights from Experts

Recognizing systemic mastocytosis early can significantly improve patient outcomes, as discussed in a recent session at the 2025 Society of Dermatology Physician Associates (SDPA) Fall Conference. The session, titled “When a Rash Is More than Skin Deep: Systemic Mastocytosis Essentials,” highlighted the importance of diagnosing this rare but impactful disease, which often first presents as a skin rash.

Dr. Hussein Abbas, an assistant professor at the University of Texas MD Anderson Cancer Center in Houston, led the discussion. He emphasized the challenges both clinicians and patients face with rare diseases that often go undiagnosed. “Systemic mastocytosis is a very rare disease, but it’s also a significant disease because it can really create a lot of symptom burden to patients,” he stated in an interview with HCPLive. He added that in some cases, the condition can affect patients’ longevity and overall quality of life.

During his presentation, Abbas aimed to equip attendees with knowledge about diagnostic pathways and key clinical clues. He underscored the necessity for collaborative management between dermatologists, allergists, and hematology/oncology specialists. “One of the main takeaways is that systemic mastocytosis is under-recognized,” he remarked. “It’s essential for us to work together to identify it.”

The disease often first presents to dermatologists or allergists due to skin-related symptoms. Patients may show signs of rashes that can be mistaken for common allergic reactions. Abbas highlighted that recognizing systemic mastocytosis requires a thorough workup, which includes measuring blood levels of tryptase, an enzyme linked to the mast cells involved in the disease.

Abbas also discussed the prevalence of cutaneous mastocytosis, noting that most patients with this condition also have systemic involvement. He categorized the cutaneous manifestations into three main types, including maculopapular cutaneous mastocytosis (MPCM). “MPCM presents as brown, reddish lesions on the skin,” he explained. “These lesions often have a characteristic shape and can provoke a reaction when stimulated.”

For further insights and tips on identifying systemic mastocytosis, viewers can access the complete session video. The quotes shared in the interview were edited for clarity, and Abbas reported no relevant financial disclosures.

The session at the SDPA conference not only raised awareness about systemic mastocytosis but also highlighted the critical role of early diagnosis in improving patient care. By fostering collaboration among specialists, healthcare providers can enhance the recognition and treatment of this rare disorder.